ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Sanofi-Aventis (Suisse) SA - Efluelda 0.7 ml, suspension injectable en seringue préremplie
6770401
Efluelda 0.7 mlsuspension injectable en seringue préremplie
J07BB02Influenza, Inactivated, Split Virus Or Surface Antigen
21.07.2021  
Composition
haemagglutininum influenzae A (H1N1) (Virus souche A/Michigan/45/2015 (H1N1)-like: reassortant virus NYMC X-275 derived from A/Michigan/45/2015) 60 µg, haemagglutininum influenzae A (H3N2) (Virus souche A/Singapore/INFIMH-16-0019/2016 (H3N2)-like: reassortant virus IVR-186 derived from A/Singapore/INFIMH-16-0019/2016 ) 60 µg, haemagglutininum influenzae B (Virus souche B/Phuket/3073/2013 (Yamagata lineage) (wild type)) 60 µg, haemagglutininum influenzae B (Virus souche B/Colorado/06/2017-like: reassortant virus NYMC BX-69A derived from B/Maryland/15/2016 (Victoria lineage)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.7 ml corresp. natrium 2.72 mg.
Packungsbestandteile
suspension injectable en seringue préremplie
 
 
Active AgentDose
Haemagglutininum Influenzae a (H1N1) (Virus Souche A/michigan/45/2015 (H1N1)-Like: Reassortant Virus nymc X-275 Derived from A/michigan/45/2015)60µg / 0.7ml
Haemagglutininum Influenzae a (H3N2) (Virus Souche A/singapore/infimh-16-0019/2016 (H3N2)-Like: Reassortant Virus Ivr-186 Derived from A/singapore/infimh-16-0019/2016 )60µg / 0.7ml
Haemagglutininum Influenzae b (Virus Souche B/colorado/06/2017-Like: Reassortant Virus nymc Bx-69A Derived from B/maryland/15/2016 (Victoria Lineage))60µg / 0.7ml
 
Inactive agentsDose
Disodium Phosphate 
Haemagglutininum Influenzae b (Virus Souche B/phuket/3073/2013 (Yamagata Lineage) (Wild Type))60µg / 0.7ml
Sodium Chloride 
Sodium Dihydrogenophosphate Anhydrate 
Octoxinolum-9 
Package numberPackage SizeEFPCPCategorySLOut of trade (MedRef)
No entries have been found.
2024 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home